Next Article in Journal
Lymphocytes of Patients with Alzheimer’s Disease Display Different DNA Damage Repair Kinetics and Expression Profiles of DNA Repair and Stress Response Genes
Next Article in Special Issue
Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
Previous Article in Journal / Special Issue
Urinary Bladder Cancer Susceptibility Markers. What Do We Know about Functional Mechanisms?
Int. J. Mol. Sci. 2013, 14(6), 12367-12379; doi:10.3390/ijms140612367
Article

Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder

1
, 1
, 2
, 3
, 1
, 1
 and 1,*
Received: 22 April 2013; in revised form: 1 June 2013 / Accepted: 3 June 2013 / Published: 10 June 2013
(This article belongs to the Special Issue Molecular Research in Urology)
View Full-Text   |   Download PDF [498 KB, uploaded 19 June 2014]   |   Browse Figures
Abstract: The orphan GPR87 has recently been matched with its ligand LPA, which is a lipid mediator with multiple physiological functions, including cancer cell proliferation. This study aimed to clarify the role of GPR87 in urothelial carcinoma of the bladder. GPR87 expression was assessed in seven human bladder cancer cell lines. A replication-deficient recombinant adenoviral vector expressing shRNA targeting GPR87 (Ad-shGPR87), was constructed. Gene silencing was carried out using Ad-shGPR87. Immunohistochemical analysis was performed for transurethral resection of bladder tumor samples from 71 patients with non-muscle-invasive bladder cancer. We observed GPR87 expression in five of the seven cell lines, and silencing GPR87 gene expression significantly reduced cell viability. GPR87 expression was positive in 38 (54%) of 71 tumors. Ki-67 index was associated with positive GPR87 staining status (p < 0.0001). Patients with GPR87-positive tumors had shorter intravesical recurrence-free survival than those with GPR87-negative tumors (p = 0.010). Multivariate analysis revealed that GPR87 staining status was an independent prognostic parameter for intravesical recurrence (p = 0.041). Progression from non-muscle-invasive to muscle-invasive tumor was more frequently observed in patients with GPR87-positive tumors, although this trend did not reach statistical significance (p = 0.056). These results warrant further prospective studies to clarify the role of GPR87 expression in intravesical recurrence and progression in bladder cancer.
Keywords: GPR87; non-muscle-invasive bladder cancer; intravesical recurrence; progression GPR87; non-muscle-invasive bladder cancer; intravesical recurrence; progression
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Okazoe, H.; Zhang, X.; Liu, D.; Shibuya, S.; Ueda, N.; Sugimoto, M.; Kakehi, Y. Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder. Int. J. Mol. Sci. 2013, 14, 12367-12379.

AMA Style

Okazoe H, Zhang X, Liu D, Shibuya S, Ueda N, Sugimoto M, Kakehi Y. Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder. International Journal of Molecular Sciences. 2013; 14(6):12367-12379.

Chicago/Turabian Style

Okazoe, Homare; Zhang, Xia; Liu, Dage; Shibuya, Shinsuke; Ueda, Nobufumi; Sugimoto, Mikio; Kakehi, Yoshiyuki. 2013. "Expression and Role of GPR87 in Urothelial Carcinoma of the Bladder." Int. J. Mol. Sci. 14, no. 6: 12367-12379.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert